Integra LifeSciences Holdings Co. (NASDAQ:IART) Given Average Rating of “Reduce” by Brokerages

Integra LifeSciences Holdings Co. (NASDAQ:IART) has been assigned an average recommendation of “Reduce” from the nine research firms that are covering the stock, Marketbeat.com reports. Three equities research analysts have rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $27.25.

IART has been the topic of a number of research reports. JMP Securities cut their target price on shares of Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating on the stock in a research report on Tuesday, July 30th. Bank of America cut their price objective on shares of Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating on the stock in a report on Monday, October 7th. Truist Financial lowered their target price on shares of Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating for the company in a report on Monday, October 14th. Morgan Stanley increased their price target on Integra LifeSciences from $24.00 to $27.00 and gave the company an “underweight” rating in a research note on Monday, July 15th. Finally, BTIG Research raised Integra LifeSciences from a “sell” rating to a “neutral” rating in a research note on Monday, October 7th.

Hedge Funds Weigh In On Integra LifeSciences

Several hedge funds have recently modified their holdings of the stock. CWM LLC increased its holdings in Integra LifeSciences by 50.8% during the second quarter. CWM LLC now owns 1,262 shares of the life sciences company’s stock worth $37,000 after buying an additional 425 shares during the last quarter. Blue Trust Inc. lifted its stake in Integra LifeSciences by 100.5% in the 2nd quarter. Blue Trust Inc. now owns 886 shares of the life sciences company’s stock valued at $26,000 after purchasing an additional 444 shares during the last quarter. CANADA LIFE ASSURANCE Co increased its position in Integra LifeSciences by 1.1% during the first quarter. CANADA LIFE ASSURANCE Co now owns 49,762 shares of the life sciences company’s stock worth $1,764,000 after buying an additional 551 shares during the last quarter. Texas Permanent School Fund Corp raised its stake in Integra LifeSciences by 1.5% in the first quarter. Texas Permanent School Fund Corp now owns 59,524 shares of the life sciences company’s stock valued at $2,110,000 after buying an additional 870 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Integra LifeSciences by 7.5% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,454 shares of the life sciences company’s stock valued at $421,000 after buying an additional 1,010 shares during the last quarter. Institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Stock Up 2.7 %

Shares of IART opened at $25.45 on Tuesday. The company has a market capitalization of $1.96 billion, a P/E ratio of -282.78, a PEG ratio of 0.84 and a beta of 1.08. Integra LifeSciences has a one year low of $16.81 and a one year high of $45.42. The business’s 50 day simple moving average is $19.18 and its 200-day simple moving average is $24.29. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.20 and a quick ratio of 2.10.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings results on Monday, November 4th. The life sciences company reported $0.41 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.39 by $0.02. The business had revenue of $380.80 million for the quarter, compared to the consensus estimate of $375.81 million. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The firm’s quarterly revenue was down .4% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.76 EPS. As a group, sell-side analysts predict that Integra LifeSciences will post 2.45 EPS for the current fiscal year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.